David W. Traylor
Geen lopende functies
Profiel
Mr. David Traylor is a Managing Director at Headwaters MB LLC (Private Equity) and a Managing Director at Headwaters MB LLC.
Prior to joining Headwaters in February 2010, Mr. Traylor worked for Caris & Co., where he was focused on biopharmaceuticals.
Previously, he worked with Wedbush Pacific Growth, advising private and public biotechnology and medical device companies in various transactions including IPOs, public offerings, private offerings, mergers and acquisitions.
He began his career in the research department at Somatogen, a company pursuing a recombinant blood substitute.
After Somatogen, he led the management of programs at Affymetrix, the leading innovator in microarray technology.
In his most recent positions, he led business development at Atugen and BioSeek.
As a result of his tenure in the industry, he has well-established relationships with the venture capital community and thought leaders in the world’s leading pharmaceutical companies.
Mr. Traylor received BA degree from the University of Colorado, Boulder, in Molecular & Cellular Biology and Biochemistry in 1988 and an MBA from the Leeds School of Business at the University of Colorado, Boulder in 1995.
He is also an inventor with two issued U.S.
patents.
Eerdere bekende functies van David W. Traylor
| Bedrijven | Functie | Einde |
|---|---|---|
BioSeek, Inc.
 BioSeek, Inc. Miscellaneous Commercial ServicesCommercial Services BioSeek, an Asterand company, is improving the success rate of pharmaceutical research and development by integrating human biology from the earliest stages of drug discovery onward. Their BioMAP® Systems incorporate predictive primary human cell-based disease models that generate uniquely informative biological activity profiles for each potential drug. As a result, their technology drives the selection and development of new drug candidates. they leverage their BioMAP® Systems technology in collaborations to enhance the productivity of their pharmaceutical partners' pipelines to identify promising compounds for therapeutic development. Asterand plc acquired BioSeek on February 18, 2010. Asterand is the leading global supplier of high quality, well characterized human tissue and human tissue-based research services to drug discovery scientists. BioSeek's BioMAP® platform and primary human cell based assays are highly complementary to the human tissue-based products and services offered by Asterand. Formed in January 2006 from the merger of Asterand, a human tissue biorepository, and Pharmagene, a human tissue-based drug discovery company, Asterand plc is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical and biotechnology companies. From their offices in Royston (United Kingdom), San Francisco, California and Detroit, Michigan they have more than 90 employees focused on providing services and products to accelerate drug discovery research from target identification through to compound evaluation and drug safety. | Corporate Officer/Principal | 30-09-2003 |
Atugen AG
 Atugen AG Pharmaceuticals: MajorHealth Technology Atugen AG is a biopharmaceutical company. It develops RNAi therapeutics which focus on vivo applications in oncology and liver diseases, exploiting its proprietary oligonucleotide delivery technologies and chemically stabilized siRNA structures. Founded in 1998, the company is headquartered in Berlin, Germany | Corporate Officer/Principal | 31-08-2002 |
| DELTAGEN INC. | Corporate Officer/Principal | 30-09-2000 |
Somatogen, Inc.
 Somatogen, Inc. BiotechnologyHealth Technology Somatogen, Inc. develops specialty oxygen therapeutics. It is engaged in the research, clinical development and commercialization of genetically engineered recombinant human hemoglobin-based products. The company is located in Boulder, CO. | Corporate Officer/Principal | 31-12-1993 |
| CEA INDUSTRIES INC. | Corporate Officer/Principal | - |
Opleiding van David W. Traylor
| The University of Colorado | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| DELTAGEN INC. | Commercial Services |
| CEA INDUSTRIES INC. | Producer Manufacturing |
| Bedrijven in privébezit | 6 |
|---|---|
Somatogen, Inc.
Somatogen, Inc. BiotechnologyHealth Technology Somatogen, Inc. develops specialty oxygen therapeutics. It is engaged in the research, clinical development and commercialization of genetically engineered recombinant human hemoglobin-based products. The company is located in Boulder, CO. | Health Technology |
Affymetrix, Inc.
 Affymetrix, Inc. Medical SpecialtiesHealth Technology Affymetrix, Inc. develops, manufactures and sells products and services for genetic analysis. The company was founded by Stephen P. A. Fodor in 1992 and is headquartered in Santa Clara, CA. | Health Technology |
Headwaters MB LLC
 Headwaters MB LLC Investment Banks/BrokersFinance Headwaters MB LLC provides investment banking services to entrepreneurs, owner and operators, and business-owning families. It offers strategic merger and acquisition advice, capital raising, and special situations advisory. The company was founded by Phil Seefried and Dave Maney in 2001 and is headquartered in Denver, CO. | Finance |
Caris & Co., Inc.
 Caris & Co., Inc. Investment Banks/BrokersFinance Founded by Darren Caris in 2002, Caris & Co., Inc. is a broker/dealer headquartered in Del Mar, California. The firm is a subsidiary of B. Riley & Co. They offer research that is independent of their investment banking activities, as well as a full array of trading and execution services. Caris & Co.'s coverage includes large-, mid- and small-cap companies in the healthcare, technology, energy and consumer sectors. Their research is written for the longer-term investor with an investment horizon of at least 12 months. Caris & Co., Inc. is a member of the NASD and the SIPC. | Finance |
Atugen AG
Atugen AG Pharmaceuticals: MajorHealth Technology Atugen AG is a biopharmaceutical company. It develops RNAi therapeutics which focus on vivo applications in oncology and liver diseases, exploiting its proprietary oligonucleotide delivery technologies and chemically stabilized siRNA structures. Founded in 1998, the company is headquartered in Berlin, Germany | Health Technology |
BioSeek, Inc.
BioSeek, Inc. Miscellaneous Commercial ServicesCommercial Services BioSeek, an Asterand company, is improving the success rate of pharmaceutical research and development by integrating human biology from the earliest stages of drug discovery onward. Their BioMAP® Systems incorporate predictive primary human cell-based disease models that generate uniquely informative biological activity profiles for each potential drug. As a result, their technology drives the selection and development of new drug candidates. they leverage their BioMAP® Systems technology in collaborations to enhance the productivity of their pharmaceutical partners' pipelines to identify promising compounds for therapeutic development. Asterand plc acquired BioSeek on February 18, 2010. Asterand is the leading global supplier of high quality, well characterized human tissue and human tissue-based research services to drug discovery scientists. BioSeek's BioMAP® platform and primary human cell based assays are highly complementary to the human tissue-based products and services offered by Asterand. Formed in January 2006 from the merger of Asterand, a human tissue biorepository, and Pharmagene, a human tissue-based drug discovery company, Asterand plc is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical and biotechnology companies. From their offices in Royston (United Kingdom), San Francisco, California and Detroit, Michigan they have more than 90 employees focused on providing services and products to accelerate drug discovery research from target identification through to compound evaluation and drug safety. | Commercial Services |
